{"id":546096,"date":"2021-06-03T23:04:02","date_gmt":"2021-06-03T23:04:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=546096"},"modified":"2021-06-03T23:04:02","modified_gmt":"2021-06-03T23:04:02","slug":"progressive-supranuclear-palsy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dtx-pharma-aprinoia-therapeutics-arvinas-taubiologics-alzprotect-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/progressive-supranuclear-palsy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dtx-pharma-aprinoia-therapeutics-arvinas-taubiologics-alzprotect-and-others_546096.html","title":{"rendered":"Progressive Supranuclear Palsy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | DTx Pharma, APRINOIA Therapeutics, Arvinas, Tau-Biologics, AlzProtect and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1622694640.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Progressive Supranuclear Palsy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | DTx Pharma, APRINOIA Therapeutics, Arvinas, Tau-Biologics, AlzProtect and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1622694640.jpeg\" alt=\"Progressive Supranuclear Palsy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | DTx Pharma, APRINOIA Therapeutics, Arvinas, Tau-Biologics, AlzProtect and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Progressive Supranuclear Palsy Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Progressive supranuclear palsy<\/strong> is a rare degenerative neurological disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking. The condition is caused by the gradual damage of brain cells. The neuropathological hallmark of PSP is a biochemical alteration in the tau protein, which results in a neurodegeneration and gliosis in the basal ganglia, brainstem, prefrontal cortex and cerebellum.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/progressive-supranuclear-palsy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Progressive Supranuclear Palsy Pipeline<\/a><\/strong><strong> Insight, 2021<\/strong>&rdquo; report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Progressive Supranuclear Palsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Progressive supranuclear palsy Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Retrotope<\/li>\n<li>Woolsey Pharmaceuticals<\/li>\n<li>UCB<\/li>\n<li>Novartis Pharmaceuticals<\/li>\n<li>EmeraMed<\/li>\n<li>Aquinnah Pharmaceuticals<\/li>\n<li>DTx Pharma<\/li>\n<li>APRINOIA Therapeutics<\/li>\n<li>Arvinas<\/li>\n<li>Tau-Biologics<\/li>\n<li>AlzProtect<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/progressive-supranuclear-palsy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/progressive-supranuclear-palsy-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Progressive supranuclear palsy report covers around 15+ products under different phases of clinical development like<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Late stage products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Mid-stage products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Early-stage product (Phase I) along with the details of<\/p>\n<p style=\"text-align: justify;\">&bull; Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify;\">&bull; Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/progressive-supranuclear-palsy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Progressive supranuclear palsy Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>RT001<\/li>\n<li>Fasudil<\/li>\n<li>Bepranemab (UCB 0107)<\/li>\n<li>NIO752<\/li>\n<li>NBMI<\/li>\n<li>TDP-43 stress granules<\/li>\n<li>MSUT2 programme<\/li>\n<li>Anti tau monoclonal antibody<\/li>\n<li>Tau-targeted PROTAC&reg; protein degraders<\/li>\n<li>TBL-100<\/li>\n<li>Ezeprogind<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/progressive-supranuclear-palsy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/progressive-supranuclear-palsy-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Progressive supranuclear palsy Treatment Scenario and Progressive supranuclear palsy Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Progressive Supranuclear Palsy drugs?<\/li>\n<li>How many Progressive Supranuclear Palsy drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Progressive Supranuclear Palsy?<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Progressive Supranuclear Palsy therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Progressive Supranuclear Palsy and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/progressive-supranuclear-palsy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/progressive-supranuclear-palsy-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<br \/> Executive Summary<br \/> Progressive Supranuclear Palsy: Overview<br \/> Pipeline Therapeutics<br \/> &bull; Comparative Analysis<br \/> Therapeutic Assessment<br \/> Progressive Supranuclear Palsy &ndash; DelveInsight&rsquo;s Analytical Perspective<br \/> In-depth Commercial Assessment<br \/> &bull; Progressive Supranuclear Palsy companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<br \/> Progressive Supranuclear Palsy Collaboration Deals<br \/> Late Stage Products (Phase III)<br \/> &bull; Comparative Analysis<br \/> Drug name: Company name<br \/> Drug profiles in the detailed report&hellip;..<br \/> Mid Stage Products (Phase II)<br \/> &bull; Comparative Analysis<br \/> RT001: Retrotope <br \/> Drug profiles in the detailed report&hellip;..<br \/> Early Stage Products (Phase I) <br \/> &bull; Comparative Analysis<br \/> Bepranemab (UCB 0107): UCB<br \/> Drug profiles in the detailed report&hellip;..<br \/> Preclinical\/Discovery Stage Products<br \/> &bull; Comparative Analysis<br \/> MSUT2 programme: DTx Pharma<br \/> Drug profiles in the detailed report&hellip;..<br \/> Inactive Products<br \/> &bull; Comparative Analysis<br \/> Progressive Supranuclear Palsy Key Companies<br \/> Progressive Supranuclear Palsy Key Products<br \/> Progressive Supranuclear Palsy- Unmet Needs<br \/> Progressive Supranuclear Palsy- Market Drivers and Barriers<br \/> Progressive Supranuclear Palsy- Future Perspectives and Conclusion<br \/> Progressive Supranuclear Palsy Analyst Views<br \/> Progressive Supranuclear Palsy Key Companies<br \/> Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/progressive-supranuclear-palsy-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=progressive-supranuclear-palsy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dtx-pharma-aprinoia-therapeutics-arvinas-taubiologics-alzprotect-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/progressive-supranuclear-palsy-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/progressive-supranuclear-palsy-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/progressive-supranuclear-palsy-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=progressive-supranuclear-palsy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dtx-pharma-aprinoia-therapeutics-arvinas-taubiologics-alzprotect-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Progressive Supranuclear Palsy Pipeline Progressive supranuclear palsy is a rare degenerative neurological disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking. The condition is caused by the gradual damage of brain cells. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/progressive-supranuclear-palsy-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dtx-pharma-aprinoia-therapeutics-arvinas-taubiologics-alzprotect-and-others_546096.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-546096","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=546096"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546096\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=546096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=546096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=546096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}